Ipsen : Trading update et guidances suspendues – Prévisions et OC ajustées
>Impact COVID-19 « difficile à quantifier » - Ipsen publie un communiqué dans lequel il indique que ses activités sont affectées à divers degrés dans les zones géographiques touchées par le COVID-19, la situation étant très différente d’un pays à l’autre et en constante évolution. Mais grâce à un portefeuille robuste, le groupe juge que l’impact de cette pandémie restera limité. Néanmoins, compte tenu du ralentissement économique général, des performances d’Ipsen...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.